Bis(1,4-dioxa-9-azadispiro[4.1.4.3]tetradecane) oxalic acid

Catalog No.: 
ACQFRC174
CAS No.: 
2007924-93-6
Molecular Formula: 
C24H40N2O8
Molecular Weight: 
484.59
Bis(1,4-dioxa-9-azadispiro[4.1.4.3]tetradecane) oxalic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$272.00InquiryInquiry
250mg95%$623.00InquiryInquiry
1g95%$2091.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBis(1,4-dioxa-9-azadispiro[4.1.4.3]tetradecane) oxalic acid
IUPAC Name1,4-dioxa-9-azadispiro[4.1.47.35]tetradecane hemioxalate
MDL No.MFCD30471650
Molecular FormulaC24H40N2O8
Molecular Weight484.59
SMILESO=C(O)C(O)=O.O1CCOC12CC3(CCC2)CNCC3.O4CCOC45CC6(CCC5)CNCC6
InChI KeySAKULPIUWNOIGK-UHFFFAOYSA-N
Synonymbis(1,4-dioxa-9-azadispiro[4.1.4.3]tetradecane);1,4-Dioxa-9-azadispiro[4.1.4.3]tetradecane, ethanedioate (2:1);1,4-dioxa-9-azadispiro[4.1.4?.3?]tetradecane hemioxalate;1,4-dioxa-9-azadispiro[4.1.47.35]tetradecane hemioxalate
CAS No.2007924-93-6
PubChem CID127263574

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACQFRC174 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQFRC174 route product structure diagram
    ACQFRC1742007924-93-6
Inquiry

2. ACQFRC174 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQFRC174 route product structure diagram
    ACQFRC1742007924-93-6
Inquiry

3. ACQFRC174 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQFRC174 route product structure diagram
    ACQFRC1742007924-93-6
Inquiry

Comments (0)